A phase I/II trial of the proteasome inhibitor PS0341 (Velcade) [bortezomib] in combination with the anti-CD20 antibody, rituximab in patients with recurrent follicular lymphoma, mantle cell lymphoma (MCL) and Waldenstrom's macroglobulinaemia (WM)

Trial Profile

A phase I/II trial of the proteasome inhibitor PS0341 (Velcade) [bortezomib] in combination with the anti-CD20 antibody, rituximab in patients with recurrent follicular lymphoma, mantle cell lymphoma (MCL) and Waldenstrom's macroglobulinaemia (WM)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Nov 2010

At a glance

  • Drugs Bortezomib; Rituximab
  • Indications Follicular lymphoma; Mantle-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 26 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top